Apimeds Pharmaceuticals US (APUS) Liabilities and Shareholders Equity (2023 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Liabilities and Shareholders Equity came in at $164.2 million in Q4 2025, up 1257338.43% YoY from N/an in Q4 2024, and up 1674.95% on a QoQ basis from $9.3 million in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Liabilities and Shareholders Equity (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $164.2 million in Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 1257338.43% year-over-year to $164.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $184.2 million (up 1410946.62% YoY) and the FY2025 annual result came in at $164.2 million, up 1257338.43% from the prior year.
- Liabilities and Shareholders Equity climbed to $164.2 million in Q4 2025, from $9.3 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $164.2 million in Q4 2025 to a low of $13057.0 in Q4 2024.
- A 3-year average of $30.8 million and a median of $4.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 96.91% — and 2025, when it surged 1257338.43%.
- Tracing APUS's Liabilities and Shareholders Equity over 3 years: stood at $422076.0 in 2023, then slumped by 96.91% to $13057.0 in 2024, then surged by 1257338.43% to $164.2 million in 2025.
- The last three Liabilities and Shareholders Equity figures came in at $164.2 million (Q4 2025), $9.3 million (Q3 2025), and $10.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 6.18 Bn |
| 10 | Apimeds Pharmaceuticals US | 7.48 Mn | 7.48 Mn | - | 127.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 164.18 Mn |
| Sep 30, 2025 | 9.25 Mn |
| Jun 30, 2025 | 10.55 Mn |
| Mar 31, 2025 | 259,904.00 |
| Dec 31, 2024 | 13,057.00 |
| Dec 31, 2023 | 422,076.00 |